Abstract submission is now open! Send us your research through Jan. 26, 2024 to present at the 27th Annual Meeting.
The ASGCT Board of Directors and the Society's officers have full responsibility for the management, direction and control of the business, policies and affairs of ASGCT, subject only to limitations set forth in the Society's Articles of Incorporation and Bylaws. Learn more about the Board and Officers below.
Jeffrey Chamberlain, PhD, President (2023-2024)
Paula Cannon, PhD, President Elect
Terence R. Flotte, MD, Vice President (2023-2026)
Isabelle Riviere, PhD, Secretary
Federico Mingozzi, PhD, Treasurer
Aravind Asokan, PhD
Hildegard Büning, PhD
Lindsey George, MD
Rayne Rouce, MD
Jennifer Wellman, MS, Membership Council Chair
Maria-Grazia Roncarolo, MD, Clinical & Translational Council Chair
Punam Malik, MD, Science + Education Council Chair
Daniel E. Bauer, MD, PhD
Kah-Whye Peng, PhD
Roland W. Herzog, PhD, Ex-Officio
Hans-Peter Kiem, MD, PhD, Immediate Past President
In order to better meet the increasing needs of our different constituencies, ASGCT embarked on a strategic planning summit in 2015. Learn more about the five goals of the Society.
Read the full Society Bylaws, which were amended and restated in May 2017.
May 7-11, 2024 | Baltimore, MD
© 2000-2023 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico